ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1260

Longitudinal Relationships Between Depression, Anxiety and Cognition in Lupus
Abstract Number: 0302

Longitudinal Study of Acute SLE Flare Reveals Dynamic Changes in Multiple Immune Cell Subsets
Abstract Number: 1114

Longitudinally Assessed Structural Abnormalities on MRI and Relative Contributions to Risk of Incident Radiographic Knee Osteoarthritis over 10 Years of Follow-up
Abstract Number: 1670

Low Copy Number of Long C4 Genes Is a Genetic Risk Factor for Childhood Onset SLE (cSLE) but Is Associated with Higher Age of Disease Onset
Abstract Number: 1277

Low Cost Composite Markers to Differentiate Infection from Disease Activity in a Febrile Patient with Systemic Lupus Erythematosus
Abstract Number: 1777

Low Dose Aspirin to Prevent Pre-eclampsia in SLE Pregnancies – Counselling Helps to Realize Our Full Potential
Abstract Number: 0559

Low Frequency of ANA/DFS70 Pattern Positive Result in a Large Cohort of Autoimmune/autoinflammatory Diseases Compared with First Degree Relatives and Healthy Controls Evaluated in a Single Hospital from Colombia
Abstract Number: 1924

Low Immunogenicity in Patients with Giant Cell Arteritis Treated with Tocilizumab: 3-Year Results from the Randomized Controlled Portion and the Open-Label Follow-Up of a Phase 3 Trial
Abstract Number: 0435

Low Incidence of Coronavirus Disease 2019 (COVID-19) Infection in Patients on Biologic Infusion Therapies at a Community Rheumatology Practice
Abstract Number: 0938

Low Preconceptional Complement Level Is Related with an Adverse Obstetric Outcome in a Multicentric Cohort of Pregnancy in Patients with APS and aPL Positivity
Abstract Number: PP02

Low- and Hi-Tech Tools for Enhancing Patient-Hospital Care Team Communication in the Context of Rare Disease
Abstract Number: 0699

Lumbar Spine Stenosis Treatment : Is Surgery Better Than Medical Treatment in Afro-Descendant Populations ?
Abstract Number: 1297

Lupus Antibodies in Relation to Malignancy
Abstract Number: 1680

Lupus Anticoagulant as a Predictor of Adverse Outcomes in Children with Venous Thromboembolism
Abstract Number: 1298

Lupus Damage Free-Survival by Age at Diagnosis: A Retrospective Incident Lupus Cohort

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].